A new trading day began on Tuesday, with Autolus Therapeutics plc ADR (NASDAQ: AUTL) stock price down -1.34% from the previous day of trading, before settling in for the closing price of $2.99. AUTL’s price has ranged from $2.92 to $7.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 190.29%. Meanwhile, its annual earnings per share averaged 24.87%. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
Let’s determine the extent of company efficiency that accounts for 463 employees. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 56.27%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.45 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.87% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Here are Autolus Therapeutics plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Looking closely at Autolus Therapeutics plc ADR (NASDAQ: AUTL), its last 5-days average volume was 2.27 million, which is a jump from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 7.78%. Additionally, its Average True Range was 0.31.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 3.30%, which indicates a significant decrease from 5.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.19% in the past 14 days, which was higher than the 70.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.86, while its 200-day Moving Average is $4.48. However, in the short run, Autolus Therapeutics plc ADR’s stock first resistance to watch stands at $3.01. Second resistance stands at $3.06. The third major resistance level sits at $3.13. If the price goes on to break the first support level at $2.89, it is likely to go to the next support level at $2.82. Now, if the price goes above the second support level, the third support stands at $2.77.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
With a market capitalization of 785.05 million, the company has a total of 266,094K Shares Outstanding. Currently, annual sales are 1,700 K while annual income is -208,380 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,270 K.
